
Valereum PLC stock has moved from obscure microcap to one of the most talked‑about names on London’s Aquis market in late 2025. A proposed USD $200 million financing package and plans for a US listing have driven a spectacular re‑rating – but also raised big questions about dilution, execution risk and the sustainability of the rally.